TickerStat.comEloxx Pharmaceuticals annual operating income
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Operating Income Growth & History (ELOX)
Eloxx Pharmaceuticals's operating income was −$6.4M for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$6.4M | −$4.0M | — |
| 2024 | 2024-12-31 | −$2.5M | $14.8M | — |
| 2023 | 2023-12-31 | −$17.3M | $17.1M | — |
| 2022 | 2022-12-31 | −$34.4M | $31.6M | — |
| 2021 | 2021-12-31 | −$66.0M | −$32.6M | — |
| 2020 | 2020-12-31 | −$33.5M | $17.1M | — |
| 2019 | 2019-12-31 | −$50.6M | −$3.0M | — |
| 2018 | 2018-12-31 | −$47.6M | −$27.2M | — |
| 2017 · Dec 31 | 2017-12-31 | −$20.4M | −$10.6M | — |
| 2017 · Jun 30 | 2017-06-30 | −$4.6M | $6.6M | — |
| 2016 · Dec 31 | 2016-12-31 | −$9.8M | −$3.6M | — |
| 2016 · Jun 30 | 2016-06-30 | −$11.2M | $6.9M | — |
| 2015 · Dec 31 | 2015-12-31 | −$6.3M | — | — |
| 2015 · Jun 30 | 2015-06-30 | −$18.1M | −$8.9M | — |
| 2014 | 2014-06-30 | −$9.1M | −$4.5M | — |
| 2013 | 2013-06-30 | −$4.7M | $761,028 | — |
| 2012 | 2012-06-30 | −$5.4M | $2.5M | — |
| 2011 | 2011-06-30 | −$7.9M | −$3.1M | — |
| 2010 | 2010-06-30 | −$4.8M | — | — |
Eloxx Pharmaceuticals quarterly operating income
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$4.5M | −$2.9M | — |
| Q1 2026 | 2026-03-31 | −$3.8M | −$2.6M | — |
| Q2 2025 | 2025-06-30 | −$1.6M | — | — |
| Q1 2025 | 2025-03-31 | −$1.2M | — | — |
| Q4 2023 | 2023-12-31 | −$4.0M | $2.0M | — |
| Q3 2023 | 2023-09-30 | −$3.6M | $3.5M | — |
| Q2 2023 | 2023-06-30 | −$4.1M | $6.2M | — |
| Q1 2023 | 2023-03-31 | −$5.5M | $5.5M | — |
| Q4 2022 | 2022-12-31 | −$6.0M | $5.6M | — |
| Q3 2022 | 2022-09-30 | −$7.1M | $3.1M | — |
| Q2 2022 | 2022-06-30 | −$10.3M | $25.4M | — |
| Q1 2022 | 2022-03-31 | −$11.0M | −$2.5M | — |
| Q4 2021 | 2021-12-31 | −$11.6M | −$5.8M | — |
| Q3 2021 | 2021-09-30 | −$10.2M | −$3.9M | — |
| Q2 2021 | 2021-06-30 | −$35.7M | −$28.1M | — |
| Q1 2021 | 2021-03-31 | −$8.4M | $5.4M | — |
| Q4 2020 | 2020-12-31 | −$5.8M | $5.7M | — |
| Q3 2020 | 2020-09-30 | −$6.3M | $6.5M | — |
| Q2 2020 | 2020-06-30 | −$7.6M | $6.7M | — |
| Q1 2020 | 2020-03-31 | −$13.8M | −$1.8M | — |
| Q4 2019 | 2019-12-31 | −$11.5M | $2.6M | — |
| Q3 2019 | 2019-09-30 | −$12.8M | −$1.4M | — |
| Q2 2019 | 2019-06-30 | −$14.3M | −$768,000 | — |
| Q1 2019 | 2019-03-31 | −$12.0M | −$3.4M | — |
| Q4 2018 | 2018-12-31 | −$14.1M | −$3.5M | — |
| Q3 2018 | 2018-09-30 | −$11.4M | −$7.4M | — |
| Q2 2018 | 2018-06-30 | −$13.5M | −$10.4M | — |
| Q1 2018 · Mar 31 | 2018-03-31 | −$8.5M | −$5.9M | — |
| Q4 2017 | 2017-12-31 | −$10.6M | −$9.1M | — |
| Q1 2018 · Sep 30 | 2017-09-30 | −$4.0M | −$1.8M | — |
| Q4 2017 | 2017-06-30 | −$3.2M | −$1.8M | — |
| Q1 2017 · Mar 31 | 2017-03-31 | −$2.6M | $2.3M | — |
| Q4 2016 | 2016-12-31 | −$1.5M | $2.3M | — |
| Q1 2017 · Sep 30 | 2016-09-30 | −$2.2M | −$1.1M | — |
| Q4 2016 | 2016-06-30 | −$1.4M | −$477,489 | — |
| Q1 2016 · Mar 31 | 2016-03-31 | −$4.9M | −$3.7M | — |
| Q4 2015 | 2015-12-31 | −$3.8M | $7.0M | — |
| Q1 2016 · Sep 30 | 2015-09-30 | −$1.2M | $4.0M | — |
| Q4 2015 | 2015-06-30 | −$919,027 | $2.8M | — |
| Q3 2015 | 2015-03-31 | −$1.2M | $903,948 | — |
| Q2 2015 | 2014-12-31 | −$10.7M | −$9.2M | — |
| Q1 2015 | 2014-09-30 | −$5.2M | −$3.4M | — |
| Q4 2014 | 2014-06-30 | −$3.7M | −$2.6M | — |
| Q3 2014 | 2014-03-31 | −$2.1M | −$1.1M | — |
| Q2 2014 | 2013-12-31 | −$1.6M | −$288,860 | — |
| Q1 2014 | 2013-09-30 | −$1.8M | −$506,576 | — |
| Q4 2013 | 2013-06-30 | −$1.1M | $506,490 | — |
| Q3 2013 | 2013-03-31 | −$1.0M | $64,455 | — |
| Q2 2013 | 2012-12-31 | −$1.3M | $156,091 | — |
| Q1 2013 | 2012-09-30 | −$1.2M | $33,992 | — |
| Q4 2012 | 2012-06-30 | −$1.6M | $1.3M | — |
| Q3 2012 | 2012-03-31 | −$1.1M | $259,072 | — |
| Q2 2012 | 2011-12-31 | −$1.5M | $48,899 | — |
| Q1 2012 | 2011-09-30 | −$1.3M | $925,246 | — |
| Q4 2011 | 2011-06-30 | −$2.8M | — | — |
| Q3 2011 | 2011-03-31 | −$1.4M | — | — |
| Q2 2011 | 2010-12-31 | −$1.5M | — | — |
| Q1 2011 | 2010-09-30 | −$2.2M | — | — |
Eloxx Pharmaceuticals operating income trends
Over the last five fiscal years, Eloxx Pharmaceuticals's operating income increased from −$33.5M to −$6.4M, a change of $27.0M. The latest reported quarter, Q2 2026, shows −$4.5M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...